With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
While it’s obvious that six prostate radiation treatments come at the fraction of the costs of, say, abiraterone in the setting of low-volume metastatic disease, this cost-effective analysis indicates it incurs lower overall costs than even ADT alone. | Lester-Coll, JAMA Netw Open 2021